ArticleInternational journal of general medicine2026
Identification of Bioactive Compounds and Molecular Targets of Compound Herbs Against Stomach Adenocarcinoma: A Network Pharmacology Approach.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The therapeutic effects of compound herbs (Radix Paeoniae Rubra, Radix Cirsii Japonici, Gentianae Radix Et Rhizoma, and Cardeniae Fructus) on stomach adenocarcinoma (STAD) remain unclear. Methods: Active ingredients and their targets from the herbal combination were obtained using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. STAD-related targets were collected from the GeneCards database, and the TCGA-STAD dataset was downloaded from The Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) between STAD and normal tissues were screened. The intersection of DEGs, drug targets, and STAD-related targets was taken to determine key targets. A protein-protein interaction (PPI) network was built and hub genes were identified. Functional enrichment analysis and molecular docking of the hub genes were performed. The Cell Counting Kit-8 (CCK8) assay was used to evaluate the effects of the active ingredients on the proliferation of Stomach Gastric Carcinoma cell line 7901 (SGC-7901) and MaKuNo cell line 45 (MKN-45) cells. The Transwell assay was used to evaluate the effect of quercetin on the migration ability of SGC-7901 and MKN-45 cells. Results: A total of 67 key targets were obtained, among which five hub genes-ESR1 (Estrogen receptor 1), FOS (FBJ murine osteosarcoma viral oncogene homolog), HSP90AA199 (Heat shock protein 90 alpha family class A member 1), JUN (Avian sarcoma virus 17 oncogene homolog), and MMP9 (Matrix Metallopeptidase 9)-were identified. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated that these hub genes were significantly associated with the T Helper 17 (Th17) Cell differentiation pathway. Molecular docking predictions suggested that active ingredients such as quercetin could bind effectively to the hub genes, with quercetin showing the strongest binding affinity to FOS. Cell experiments further confirmed that quercetin exhibited the most potent inhibitory effect on the proliferation of STAD cells, with a half-maximal inhibitory concentration (IC50) value of 4 μM. Furthermore, quercetin can significantly inhibit the migration of SGC-7901 and MKN-45 cells. Conclusion: This study identified five key targets and active compounds in herbal compounds for STAD treatment. These results suggest that quercetin may inhibit STAD progression by targeting FOS, and may have therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.